Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 22, 2024
Period End
December 31, 2023
Security
IDXX
One revenue dollarkept$0.23
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2023 10-K shows a strong year driven by pricing and recurring diagnostic revenue.

Total revenue rose 8.7% reported (8.8% organic) to $3.66 billiona, with Companion Animal Group (CAG) growing 9.6% to $3.35 billion and recurring CAG Diagnostics revenue reaching $2.94 billion, about 80% of consolidated revenue. Gross margin expanded 30 bps to 59.8%, and operating income rose 22.1% to $1.10 billion (30.0% of revenue), helped by a $16 million customer contract resolution gain and lower R&D after a prior-year $84 million technology license charge. Net income was $845 million, and diluted EPS was $10.06, up from $8.03.

The balance sheet and cash flow improved meaningfully. Operating cash flow was $906.5 millionb, up from $543.0 million, and cash ended at $453.9 million versus $112.5 million a year earlier. Gross debt to Adjusted EBITDA was 0.74x and net debt to Adjusted EBITDA was 0.39x, well inside the 3.5x covenant.

The company repurchased only $71.9 millionc of stock in 2023, versus $819.7 million in 2022, and it has never paid a cash dividend. Management's 2024 outlook includes a projected effective tax rate of about 22%, capital expenditures of about $180 million, and an approximately $77 million acquisition closed on February 1, 2024.

Key risks flagged in the filing include intensifying competition, consolidation of veterinary practices into corporate groups and buying consortiums, sole-source supplier dependence (notably Ortho for chemistry slides), AI-related regulatory and reputational exposure, and a pending state supreme court ruling on a royalty lawsuit with a $50 milliond claim against which $27.5 million has been accrued. U.S. same-store clinical visits declined about 0.5% in 2023, so growth relied on pricing and diagnostic utilization rather than visit volume.

Key Highlights

  1. Revenue grew 8.7% (8.8% organic) to $3.66 billion; CAG revenue grew 9.6% to $3.35 billion.
  2. Recurring CAG Diagnostics revenue of $2.94 billion represents roughly 80% of consolidated revenue, supporting earnings durability.
  3. Operating income rose 22.1% to $1.10 billion, with operating margin expanding to 30.0% from 26.7%.
  4. Diluted EPS increased to $10.06 from $8.03, and net income reached $845 million.
  5. Operating cash flow nearly doubled to $906.5 million, and year-end cash rose to $453.9 million.
  6. Balance sheet is conservative: net debt to Adjusted EBITDA of 0.39x versus a 3.5x covenant limit.
  7. Share repurchases fell sharply to $71.9 million from $819.7 million, and the company does not pay a dividend.

Follow one dollar

Of each $1.00 of revenue in FY2023, IDEXX Laboratories kept $0.23.

  1. Revenue$3.66B100.0%
  2. Cost of revenue−$1.47B40.2%
  3. Gross profit$2.19B59.8%
  4. Operating costs−$1.09B29.9%
  5. Operating income$1.10B30.0%
  6. Interest, other & tax−$252.1M6.9%
  7. Net income$845.0M23.1%
Computed from 10-KFY2023filed February 22, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2023 revenue went

$3.66B
  • Cost of revenue: $1.47B, 40% of revenue
  • Other operating costs: $901.9M, 25% of revenue
  • Net income: $845.0M, 23% of revenue
  • R&D: $191.0M, 5.2% of revenue
  • Interest, other & tax: $252.1M, 6.9% of revenue

Kept 23% as net income

Full revenue history →

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$3.66B$3.37B+8.7%
Cost of Revenue$1.47B$1.36B+7.9%
Gross Profit$2.19B$2.00B+9.3%
R&D Expenses$190.95M$254.82M−25.1%
Operating Expenses$1.09B$1.11B−1.2%
Operating Income$1.10B$898.76M+22.1%
Interest Expense$41.58M$39.86M+4.3%
Net Income$845.04M$679.09M+24.4%
EPS (Basic)$10.17$8.12+25.2%
EPS (Diluted)$10.06$8.03+25.3%
Shares Outstanding (Basic)83.07M83.62M−0.7%
Shares Outstanding (Diluted)83.98M84.60M−0.7%

Frequently Asked Questions

  1. What drove IDEXX's revenue growth in 2023 given flat U.S. clinic visits?

    Growth came mainly from higher realized prices and increased diagnostic volumes per patient. U.S. same-store clinical visits declined about 0.5%, while average diagnostics revenue per practice grew about 8%. IDEXX VetLab consumables grew 12.4% and reference lab revenue grew 8.5%.

  2. How much of IDEXX's revenue is recurring, and why does it matter?

    Recurring diagnostic revenue accounted for about 80% of consolidated revenue in 2023. Consumables, rapid assay kits, reference lab services, and service contracts recur as instruments are used, which provides more predictable cash flows than one-time instrument sales, which fell 6.6% in CAG.

  3. What are the biggest risks highlighted in the 10-K?

    Key risks include intensifying competition from larger rivals and new AI-enabled entrants, consolidation of veterinary hospitals into corporate groups and buying consortiums that may shift purchasing, dependence on sole-source suppliers such as Ortho for chemistry slides, regulatory exposure (including AI, PFAS, and data privacy), and a royalty lawsuit with a claim of about $50 million, against which $27.5 million has been accrued.

  4. Is IDEXX's debt a concern for investors?

    Leverage is low. Gross debt was $948.5 million, or 0.74x Adjusted EBITDA, and net debt was $494.5 million, or 0.39x. The $1.25 billion Credit Facility had $250 million drawn at year-end, and IDEXX was in compliance with its 3.5x leverage covenant. The company expects to repay $75 million of 2024 Series B Notes from cash on hand.

  5. What is management's outlook for 2024 that investors should note?

    The filing projects an effective tax rate of about 22%, up from 20.4% in 2023, largely because 2023 benefited from one-time valuation allowance releases. Capital expenditures are planned at about $180 million. Management also expects continued cost inflation in labor, commodities, energy, and transportation, which may pressure margins if price increases do not fully offset it.